FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387098523> ?p ?o ?g. }

• W4387098523 endingPage "4871" @default.
• W4387098523 startingPage "4858" @default.
• W4387098523 abstract "The determination of tumor human epidermal growth factor receptor type 2 (HER2) status is of increasing importance with the recent approval of more efficacious HER2-targeted treatments. There is a lack of suitable methods for clinical in vivo HER2 expression assessment. Affibody molecules are small affinity proteins ideal for imaging detection of receptors, which are engineered using a small (molecular weight 6.5 kDa) nonimmunoglobulin scaffold. Labeling of Affibody molecules with positron emitters enabled the development of sensitive and specific agents for molecular imaging. The development of probes for SPECT would permit the use of Affibody-based imaging in regions where PET is not available. In this first-in-human study, we evaluated the safety, biodistribution, and dosimetry of the 99mTc-ZHER2:41071 Affibody molecule developed for SPECT/CT imaging of HER2 expression. Methods: Thirty-one patients with primary breast cancer were enrolled and divided into three cohorts (injected with 500, 1000, or 1500 µg ZHER2:41071) comprising at least five patients with high (positive) HER2 tumor expression (IHC score 3+ or 2+ and ISH positive) and five patients with low (IHC score 2+ or 1+ and ISH negative) or absent HER2 tumor expression. Patients were injected with 451 ± 71 MBq 99mTc-ZHER2:4107. Planar scintigraphy was performed after 2, 4, 6 and 24 h, and SPECT/CT imaging followed planar imaging 2, 4 and 6 h after injection. Results: Injections of 99mTc-ZHER2:41071 were well tolerated and not associated with adverse events. Normal organs with the highest accumulation were the kidney and liver. The effective dose was 0.019 ± 0.004 mSv/MBq. Injection of 1000 µg provided the best standard discrimination between HER2-positive and HER2-low or HER2-negative tumors 2 h after injection (SUVmax 16.9 ± 7.6 vs. 3.6 ± 1.4, p < 0.005). The 99mTc-ZHER2:41071 uptake in HER2-positive lymph node metastases (SUVmax 6.9 ± 2.4, n = 5) was significantly (p < 0.05) higher than that in HER2-low/negative lymph nodes (SUVmax 3.5 ± 1.2, n = 4). 99mTc-ZHER2:41071 visualized hepatic metastases in a patient with liver involvement. Conclusions: Injections of 99mTc-ZHER2:41071 appear safe and exhibit favorable dosimetry. The protein dose of 1000 µg provides the best discrimination between HER2-positive and HER2-low/negative expression of HER2 according to the definition used for current HER2-targeting drugs." @default.
• W4387098523 created "2023-09-28" @default.
• W4387098523 creator A5004853883 @default.
• W4387098523 creator A5008070853 @default.
• W4387098523 creator A5014071440 @default.
• W4387098523 creator A5029710444 @default.
• W4387098523 creator A5033302171 @default.
• W4387098523 creator A5038740834 @default.
• W4387098523 creator A5038864187 @default.
• W4387098523 creator A5078197222 @default.
• W4387098523 creator A5079045120 @default.
• W4387098523 creator A5082324470 @default.
• W4387098523 creator A5088872401 @default.
• W4387098523 creator A5090698986 @default.
• W4387098523 date "2023-01-01" @default.
• W4387098523 modified "2023-10-16" @default.
• W4387098523 title "Phase I clinical evaluation of ^99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer" @default.
• W4387098523 cites W2000237324 @default.
• W4387098523 cites W2016016353 @default.
• W4387098523 cites W2030943891 @default.
• W4387098523 cites W2031606304 @default.
• W4387098523 cites W2040415740 @default.
• W4387098523 cites W2044957636 @default.
• W4387098523 cites W2066420422 @default.
• W4387098523 cites W2101883285 @default.
• W4387098523 cites W2120627364 @default.
• W4387098523 cites W2122767481 @default.
• W4387098523 cites W2126661996 @default.
• W4387098523 cites W2132840811 @default.
• W4387098523 cites W2134450909 @default.
• W4387098523 cites W2154568434 @default.
• W4387098523 cites W2157434805 @default.
• W4387098523 cites W2226721696 @default.
• W4387098523 cites W2267591082 @default.
• W4387098523 cites W2285875128 @default.
• W4387098523 cites W2318605753 @default.
• W4387098523 cites W2345989459 @default.
• W4387098523 cites W2520541785 @default.
• W4387098523 cites W2592024682 @default.
• W4387098523 cites W2652858501 @default.
• W4387098523 cites W2750630611 @default.
• W4387098523 cites W2769853159 @default.
• W4387098523 cites W2778515750 @default.
• W4387098523 cites W2806209829 @default.
• W4387098523 cites W2979675991 @default.
• W4387098523 cites W2996630100 @default.
• W4387098523 cites W3010994824 @default.
• W4387098523 cites W3012380787 @default.
• W4387098523 cites W3012530083 @default.
• W4387098523 cites W3036324525 @default.
• W4387098523 cites W3039382268 @default.
• W4387098523 cites W3050283202 @default.
• W4387098523 cites W3121365664 @default.
• W4387098523 cites W3134334047 @default.
• W4387098523 cites W3135115453 @default.
• W4387098523 cites W3138977263 @default.
• W4387098523 cites W3183150027 @default.
• W4387098523 cites W3211162368 @default.
• W4387098523 cites W4281640394 @default.
• W4387098523 cites W4281675214 @default.
• W4387098523 cites W4281921562 @default.
• W4387098523 cites W4296962003 @default.
• W4387098523 cites W4308766741 @default.
• W4387098523 cites W4309164570 @default.
• W4387098523 cites W4310949417 @default.
• W4387098523 cites W4313424104 @default.
• W4387098523 cites W4313837147 @default.
• W4387098523 cites W4366819610 @default.
• W4387098523 cites W4380369726 @default.
• W4387098523 cites W4384132714 @default.
• W4387098523 doi "https://doi.org/10.7150/thno.86770" @default.
• W4387098523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37771776" @default.
• W4387098523 hasPublicationYear "2023" @default.
• W4387098523 type Work @default.
• W4387098523 citedByCount "0" @default.
• W4387098523 crossrefType "journal-article" @default.
• W4387098523 hasAuthorship W4387098523A5004853883 @default.
• W4387098523 hasAuthorship W4387098523A5008070853 @default.
• W4387098523 hasAuthorship W4387098523A5014071440 @default.
• W4387098523 hasAuthorship W4387098523A5029710444 @default.
• W4387098523 hasAuthorship W4387098523A5033302171 @default.
• W4387098523 hasAuthorship W4387098523A5038740834 @default.
• W4387098523 hasAuthorship W4387098523A5038864187 @default.
• W4387098523 hasAuthorship W4387098523A5078197222 @default.
• W4387098523 hasAuthorship W4387098523A5079045120 @default.
• W4387098523 hasAuthorship W4387098523A5082324470 @default.
• W4387098523 hasAuthorship W4387098523A5088872401 @default.
• W4387098523 hasAuthorship W4387098523A5090698986 @default.
• W4387098523 hasBestOaLocation W43870985231 @default.
• W4387098523 hasConcept C121608353 @default.
• W4387098523 hasConcept C126322002 @default.
• W4387098523 hasConcept C136339569 @default.
• W4387098523 hasConcept C142724271 @default.
• W4387098523 hasConcept C150903083 @default.
• W4387098523 hasConcept C207001950 @default.
• W4387098523 hasConcept C2775842073 @default.
• W4387098523 hasConcept C2777807558 @default.
• W4387098523 hasConcept C2778172261 @default.

• next